Project Oncology-logo

Project Oncology

ReachMD

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.
More Information

Location:

Fort Washington, PA

Networks:

ReachMD

Description:

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.

Language:

English


Episodes

What is the Role for TKIs in RCC? Highlights from the 18th Annual Meeting of the SUO

8/2/2018
More
Host: Barnett Mennen, MD Guest: Vitaly Margulis, MD Jointly provided by and Although renal cell carcinoma (RCC) accounts for only 2% to 3% of all adult cancers, for those who present with or progress to advanced RCC, the 5-year survival rate has never been above 10%. Several tyrosine-kinase inhibitors (TKIs), along with many other therapies, now occupy a preferred role in treatment of patients with advanced RCC, but this is a rapidly changing field. The emergence of immunotherapy for...

Duration:00:29:59

Oncology On-Que: Expert Answers to Common Questions for Optimizing Platinum-Refractory NSCLC Treatment

7/24/2018
More
Host: Joshua Bauml, MD Despite the importance of genomic profiling and the advent of targeted therapies, chemotherapeutic strategies remain a cornerstone treatment for patients with advanced non–small cell lung cancer (NSCLC). This includes those patients without actionable mutations in the treatment-naive setting as well as patients with NSCLC that progresses on first-line platinum therapy, and NSCLC with genetic alterations that develops resistance to targeted therapies. AXIS routinely...

Duration:00:21:00

The Impact of Cancer on the Young Adult Patient

7/18/2018
More
Guest: Denise Rokitka, MD, MPH In this segment, Dr. Rokitka describes the Adolescent and Young Adult (AYA) cancer population including what makes them unique and why they need special attention. Also discussed will be the more common cancer types seen among AYAs and what action(s) to take if a malignancy is suspected in an AYA patient. This activity is part of a series of in-depth discussions with oncology thought leaders at the Roswell Park Comprehensive Cancer Center in Buffalo, New York...

Duration:00:07:59

Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines

7/12/2018
More
Host: John J. Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender...

Duration:00:12:29

Advances in Immuno-Oncology: Evaluating a Bispecific, Bifunctional Fusion Protein

6/29/2018
More
Host: Barnett Mennen, MD Guest: James L. Gulley, MD, PhD, FACP About 20% of patients treated with anti-PD-1/PD-L1 checkpoint inhibitors respond to therapy. At issue is the existence and action of immunosuppressive cytokine transforming growth factor-beta (TGF-β) in the tumor microenvironment, which inhibits the normal anti-tumor action of natural killer cells and T cells. TGF-β is involved in many other processes of cancer progression and metastasis such as fibroid cap formation,...

Duration:00:13:59

Innovative Molecules in Immuno-Oncology: Revolutionizing Cancer Treatment

6/5/2018
More
Get a closer look at the newest development in cancer immunotherapy: the bifunctional fusion protein. Could this small but mighty protein designed to block two signaling pathways used by tumor cells to escape immune system control be the key to managing both tumor growth and metastasis? For more episodes in this series, visit ReachMD.com/IO.

Duration:00:03:59

Small Molecules in Immuno-oncology: Revolutionizing Cancer Treatment

6/5/2018
More
Get a closer look at the newest development in cancer immunotherapy: the bifunctional fusion protein. Could this small but mighty protein designed to block two signaling pathways used by tumor cells to escape immune system control be the key to managing both tumor growth and metastasis? For more episodes in this series, visit ReachMD.com/IO.

Duration:00:03:59

Clinical Debates in Multiple Myeloma: Putting Evidence Into Context

5/23/2018
More
Guest: Sagar Lonial, MD, FACP The treatment armamentarium for multiple myeloma (MM) has expanded significantly in recent years, with 6 new agents or indications approved by the US Food & Drug Administration since 2015. Treatment options now include immunomodulatory drugs, proteasome inhibitors, a histone deacetylase inhibitor, and immunotherapies, making clinical decisions much more complex. Additionally, best practices and consensus guidelines, such as those from the National...

Duration:00:40:00

Immunocellular Therapies for Relapsed/Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy

5/15/2018
More
Host: Robert Mocharnuk, MD Guest: Jae Park, MD The treatment of relapsed or refractory leukemias and lymphomas continues to be challenging, often characterized by limited therapeutic options and poor outcomes. Effective new therapies are needed for these patients. Chimeric antigen receptor (CAR) T-cell therapy represents a radical departure from current treatments by simultaneously being cell therapy, gene therapy, and immunotherapy. It promises to revolutionize the treatment of multiple...

Duration:00:15:00

Pathways in Oncology: Tools to Assure Quality Care

5/7/2018
More
Host: Stephen Edge, MD, FACS, FASCO In this segment, Dr. Edge discusses the benefits of using clinical oncology pathways in practice as well as their optimal use for patients. Also discussed will be how to best select the primary choice for treatment when using clinical oncology pathways. This activity is part of a series of in-depth discussions with oncology thought leaders at the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians....

Duration:00:18:30

Adnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes

2/28/2018
More
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG Guest: Burton S. Brodsky, MD, FACOG Low awareness of women’s risk factors and symptoms for ovarian cancer, compounded by common use of diagnostic laboratory tests that are less sensitive and not specifically approved for assessing the risk of malignant adnexal mass, are the most important reasons that the great majority of women with ovarian cancer are only diagnosed in late stage disease, when prognosis is far worse. In this CME activity,...

Duration:00:14:59

Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer

2/19/2018
More
Host: Brian P. McDonough, MD, FAAFP Human papillomavirus (HPV) infection remains one of the most common sexually transmitted infections in both females and males, with about 9 in 10 people contracting HPV at some point in their lives. Host Dr. Brian McDonough is joined by Samantha Gottlieb, medical anthropologist and author of Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer. They explore the history of Gardasil, a vaccine developed for HPV but marketed primarily as a cervical...

Duration:00:14:59

Overcoming Treatment Challenges for Tuberous Sclerosis Complex (TSC): SEGA and the Future of Seizure Management

2/16/2018
More
Guest: Darcy A. Krueger, MD, PhD Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by the systemic growth of benign, noninvasive legions. SEGAs, which are slow-growing glioneural tumors that develop near the foramen of Monro, usually develop before the age of 20 years and represent a significant morbidity and mortality burden in children and adolescents with TSC. The current standard of treatment for symptomatic SEGA is surgical resection of lesions....

Duration:00:42:29

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward

1/25/2018
More
Host: John J. Russell, MD Guest: David A. Reardon, MD Glioblastoma Multiforme (GBM) is the most common and most malignant of all glial tumors. These tumors present a challenge to the team managing the patient, as there is no curative treatment; the goal is to find the best approach and optimal role for each team member. There are a variety of treatment options, which include surgery (resection), radiotherapy, and chemotherapy. The prognosis for these patients is measured in years with...

Duration:00:13:29

What to Know About a State-of-the-Art Approach to GIST Treatment

1/17/2018
More
Host: Shira Johnson, MD Guest: Ronald DeMatteo, MD, FACS A Gastrointestinal Stromal Tumor (GIST) is a rare sarcoma that begins in the digestive tract or stomach, with an incident rate in the United States of approximately 4,000 to 6,000 cases per year. Since these tumors behave differently from other gastrointestinal cancers, they require a specialized treatment plan. Host Dr. Shira Johnson chats with Ronald DeMatteo, MD, FACS, Chair of the Department of Surgery and a surgical oncologist...

Duration:00:12:29

Cervical Cancer Screening: The Latest Research on the Impact of Different Cytology Methods

1/16/2018
More
Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. Rozemeijer K, Penning C, Siebers AG, Naber SK, Matthijsse SM, van Ballegooijen M, van Kemenade FJ, de Kok IM. Cancer Causes Control. 2016 Jan;27(1):15-25.doi: 10.1007/s10552-015-0678-1. Epub 2015 Oct 12. Background Information: In the previous audio abstract summarizing the results from these researchers from the Erasmus Medical Center in the...

Duration:00:03:29

Advancing Interdisciplinary Care in Prostate Cancer: Clinical Updates for Urology and Oncology Healthcare Professionals

1/9/2018
More
Guest: A. Oliver Sartor, MD Prostate cancer is the third leading cause of cancer death in men in the United States, accounting for 8% of all cancer deaths with an estimated 26,730 deaths in 2017. The recent development of novel hormonal agents, chemotherapy, and immunotherapy has dramatically changed the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC). Until 2010, docetaxel was the only agent approved by the US Food and Drug Administration (FDA) to treat mCRPC....

Duration:00:25:30

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

1/7/2018
More
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Duration:00:08:29

Peripheral Blood Smear: Diagnostic Clues and Algorithms

12/28/2017
More
Guest: Vishala Neppalli, MD In this segment, Dr. Vishala Neppalli discusses the importance of a peripheral blood smear review in addition to the clues obtained from both “Red Cell” morphology and “White Blood Cell” morphology and counts. This activity is part of a series of in-depth discussions with oncology thought leaders from the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians. This series was made possible through the generous...

Duration:00:22:59

Supportive and Palliative Care for the Primary Care Physician

12/28/2017
More
Guest: Amy Allen Case, MD, FAAHPM In this segment, Dr. Case describes supportive and palliative care and how that differs from hospice/end-of life care. This activity is part of a series of in-depth discussions with oncology thought leaders from the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians. This series was made possible through the generous support of BlueCross BlueShield of Western New York.

Duration:00:12:59